The 2022 DESTINY-Breast04 trial showcased a substantial survival improvement among HER2-low BC patients treated with trastuzumab-deruxtecan, with a progression-free survival (PFS) of 10 months and an overall survival (OS) of 23.4 months for patients treated with this antibody drug conjugate. This evidence concerns the gene ERBB2 and breast cancer.